NEW YORK, May 4, 2017 /PRNewswire/ --
On Wednesday, May 03, 2017, US markets saw broadbased losses with eight out of nine sectors finishing the trading sessions in red. Major US indices were mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,072.55, down 0.37%; the Dow Jones Industrial Average edged 0.04%
Wayne, Pennsylvania headquartered Egalet Corp.'s stock declined 8.08%, to close the day at $3.07. The stock recorded a trading volume of 495,757 shares, which was above its three months average volume of 300,680 shares. The Company's shares are trading 33.17% and 51.94% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the company, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have a Relative Strength Index (RSI) of 17.08. Visit us today and download your complete report on EGLT for free at:
On Wednesday, shares in Durham, North Carolina headquartered Argos Therapeutics Inc. ended the session 9.76% higher at $0.45 with a total volume of 322,474 shares traded. The stock is trading 46.46% above its 50-day moving average and 88.36% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases, have an RSI of 41.54.
On April 19th, 2017, research firm FBR & Co. reiterated its 'Market Perform' rating on the Company's stock with a decrease of the target price from $2 a share to $1.20 a share. The complimentary research report on ARGS can be accessed at:
On Wednesday, shares in Bothell, Washington headquartered Alder Biopharmaceuticals Inc. recorded a trading volume of 465,473 shares. The stock ended the day 0.46% higher at $21.80. Alder Biopharma's stock has advanced 7.92% in the last one month and 4.31% in the previous three months. The Company's shares are trading above its 50-day moving average by 0.89%. Furthermore, shares of Alder Biopharma, which discovers, develops, and commercializes therapeutic antibodies in the US, Australia, and Ireland, have an RSI of 54.06. Register for free on Stock-Callers.com and download the PDF research report on ALDR at:
Anavex Life Sciences
New York-based Anavex Life Sciences Corp.'s stock finished Wednesday's session 0.36% higher at $5.65 with a total volume of 252,785 shares traded. Over the last three months and the previous one year, Anavex Life Sciences' shares have gained 18.70% and 2.73%, respectively. The Company's shares are trading above its 200-day moving average by 30.36%. Shares of Anavex Life Sciences, which engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers, have an RSI of 45.89. Get free access to your research report on AVXL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...
Brugada syndrome is a rare genetic heart condition that affects the way electrical signals pass ...
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in ...View All